and interleukin-10 (IL-10) are thought to play pivotal roles in immune recognition, acceptance of the fetal allograft, maintenance of pregnancy and parturition. Their secretion and regulation within the third trimester uterus is, however, less well defined. We therefore investigated the release of these cytokines by third trimester amnion, chorion, placenta and decidua, and studied the influence of prostaglandin E 2 (PGE 2 ) infusion on their release in a dynamic placental cotyledon perfusion system. MCP-1 was released predominately by the chorion (78.2 ⍨ 7.3 pg/mg wet tissue weight; mean ⍨ SEM), decidua (112.4 ⍨ 5.2 pg/mg) and placenta (101.8 ⍨ 5.0 pg/mg) with low amounts from the amnion (1.3 ⍨ 0.4 pg/mg). High concentrations of IL-8 were released by the amnion (39.9 ⍨ 5.3 pg/mg), chorion (52.8 ⍨ 1.9 pg/mg), decidua (42.2 ⍨ 1.5 pg/mg) and placenta (45 ⍨ 1.3 pg/mg). Release of RANTES was not detectable from the amnion but was detected in moderate amounts from the chorion (6.0 ⍨ 1.2 pg/mg), decidua (15.2 ⍨ 1.4 pg/mg) and placenta (26.9 ⍨ 1.6 pg/mg). Low concentrations of IL-10 were secreted by the chorion (6.8 ⍨ 0.8 pg/mg), decidua (9.0 ⍨ 0.9 pg/mg) and placenta (3.3 ⍨ 0.3 pg/mg) with none detectable from the amnion. MCP-1, IL-8, RANTES and IL-10 were all released by perfused placental cotyledons. PGE 2 stimulated release of MCP-1, IL-8 and IL-10 into the maternal and of MCP-1 and IL-8 into the fetal circulation of the placenta but had no effect on RANTES release. It is suggested that MCP-1 and IL-8 may be involved in the inflammatory process of parturition and IL-10 in the protection of the fetal allograft. In addition, PGE 2 may have an important immunomodulatory role within the uterus at term.
Introduction
The control and regulation of intrauterine function during pregnancy and parturition is dependent on a delicate balance 3560 © European Society of Human Reproduction and Embryology between immune and endocrine systems. Chemokines, acting as local effectors and mediators of cell trafficking, are thought to play pivotal roles in the immune recognition and maintenance of pregnancy, acceptance of the fetal allograft and parturition. Monocyte chemotactic peptide-1 (MCP-1), and RANTES (Regulated on Activation and Normally T-cell Expressed and presumably Secreted) are chemokines whose principal role is in effecting chemotaxis of monocytes, neutrophils and T-cells respectively. IL-8, an α-chemokine, is released by many of the intrauterine tissues present during the third trimester (Elliott et al., 1998) , is found in high concentrations within amniotic fluid, and has been implicated in the initiation of infection-mediated pre-term labour (Cherouny et al., 1993) and cervical ripening (Sennstrom et al., 1997) . MCP-1, a β-chemokine, is released by many reproductive tissues, including the ovarian follicles (Arici et al., 1997) , endometrium (Arici et al., 1995) and third trimester chorio-decidua , and RANTES is released by the endometrium (Hornung et al., 1997) and a first trimester trophoblast cell line (Svinarich et al., 1996) . However, whether MCP-1 is released by amnion or placenta or RANTES by amnion, chorion, decidua or placenta during the third trimester is not known.
Interleukin-10 (IL-10) is a potent immunomodulatory cytokine that promotes development of a humoral or T-helper 2 (TH-2) type of immune response, which is associated with a successful outcome to pregnancy (Wegmann et al., 1993) . IL-10 is present in amniotic fluid throughout pregnancy and is released by most of the intrauterine structures present during the third trimester. The factors which regulate IL-10 release from these tissues and its function within the uterus at term are, however, less well defined.
It is now recognized that prostaglandin E 2 (PGE 2 ), although initially described as a potent vasodilator, is an important immunomodulator and mediator of inflammation within the uterus . During the third trimester, it is released by the amnion , chorion (Dudley et al., 1996) , decidua (Ishihara et al., 1991) and placenta (Wetzka et al., 1997) , and a rise in its concentrations within the uterus is associated with the onset of parturition. The effects of PGE 2 on the release of other cytokines such as IL-8, which may be involved in parturition, are not well understood.
The aim of this study was to investigate the release of MCP-1, IL-8, RANTES and IL-10 from third-trimester amnion, chorion, decidua and placenta and to evaluate the possible contribution of these chemokines to parturition. A dynamic dual placental cotyledon perfusion model was then used to study the influence of PGE 2 infusion on placental chemokine release and to assess whether any regulation of chemokine secretion could have implications for the immunological mechanisms involved in the maintenance of pregnancy and parturition.
Materials and methods

Tissue collection
Tissue samples for explant cultures were obtained from normal healthy women with uncomplicated pregnancies undergoing elective Caesarean section at term. Discs of amnion (12-mm diameter; wet weight 10-20 mg; n ϭ 7 different women) and chorion laeve (9-mm diameter; 15-25 mg; n ϭ 7 different women) were prepared using a cork borer, pieces of decidua (20-30 mg; n ϭ 7 different women) by curettage off the myometrium and villous placenta (20-30 mg; n ϭ 7 different women) by dissection of placental tissue. For placental perfusion studies, placentae (n ϭ 8 different placentae) were collected from normal healthy women with uncomplicated pregnancies immediately after elective Caesarean section or spontaneous delivery and were transported to the laboratory on ice. Ethical approval was obtained for this study from the local Ethics Committee.
Explant culture
Discs of amnion, chorion laeve, pieces of decidua and villous placental tissue were placed on absorbent capillary matting and maintained in culture as described previously (Brennand et al., 1995) . Four explants of each tissue were cultured from each woman. Culture medium was collected after 24 h and stored at -20°C before being assayed.
Dual perfusion of a placental cotyledon
A peripheral cotyledon was selected which was macroscopically intact with parallel chorionic artery and vein, cannulated and mounted in a perfusion chamber as described previously (Schneider et al., 1972; Schneider and Huch, 1985) , with minor modifications (Benediktsson et al., 1997) . The maternal and fetal compartments were perfused with Kreb's solution at flow rates of 10 and 6 ml/min, and gassed with 95% O 2 /5% CO 2 and 95% N 2 /5% CO 2 respectively. The perfusate on the fetal side was supplemented with dextran (20 g/l; average molecular weight 74 kDa; Sigma Chemical Co., Poole, Dorset, UK). Perfusions were started within 10 min of delivery. After a 40-min equilibration period, which permitted the residual blood to be eluted and circulatory perfusion pressures to stabilize, consecutive 10-min samples were collected from both maternal and fetal circuits. A pre-infusion sample was followed by three samples during the infusion of PGE 2 (500 pg/ml for 30 min; Upjohn Co., Kalamazoo, MI, USA) into the maternal circuit, followed by two post-infusion samples. Samples were stored at -20°C before being assayed.
The integrity and viability of each preparation was established throughout the experimental period by ensuring that: (i) the rate of perfusate input in both the fetal and maternal circuits equalled the rate of output; (ii) there was adequate exchange of O 2 from the maternal to fetal circuits (step-up pressures of Ͻ40 to 70 mm Hg in fetal perfusate); (iii) lactate concentrations remained within the normal low range (Ͻ2 mM; Benediktsson et al., 1997) ; (iv) at the end of the experiment the fetal vasculature responded to a bolus infusion of noradrenaline (20 mg; Sigma); and (v) subsequent microscopic histological investigations revealed no significant morphological changes.
Cytokine assays
Assay for MCP-1 MCP-1 was measured by an enzyme-linked immunosorbent assay (ELISA) using a peroxidase labelled Fab fragment of an antibody to 3561 MCP-1 as described previously (Ida et al., 1994; . Briefly, plates were coated overnight at 4°C with MCP-1 capture antibody [4 µg/ml in phosphate-buffered saline (PBS); Toray Industries Inc., Tokyo, Japan], then washed once in tap water and coating solution added [50 mM Tris, 5 mg/ml bovine serum albumin (BSA), 5 mM EDTA, 2% polyvinyl pyrrolidone; all reagents were from Sigma, unless otherwise stated] for 30 min. Plates were air dried and stored with a desiccant at 4°C. Samples and standards (Toray Industries, Inc., diluted in ELISA buffer; 150 mM NaCl; 100 mM Tris; 100 mM 2-methylisothizolone, Boehringer Mannheim, Lewes, Sussex, UK; 100 mM bromonitrodioxane, Boehringer Mannheim; 50 mM Phenol Red solution; 2 mM EDTA; 2 mg/ml BSA; 0.05% Tween 20 to final pH of 7.2) were added with the highest concentration of standard being 500 pg/ml. Plates were then incubated for 3 h at 23°C on an orbital plate shaker, washed (150 mM NaCl; 100 mM Tris; 0.05% Tween 20 to final pH of 7-7.5), then peroxidase-coupled detection antibody (diluted 1:200 in ELISA Buffer) was added and incubated for 45 min at 23°C on an orbital shaker. Plates were then washed and substrate (0.3 g/l urea-hydrogen peroxide; 0.1 g/l tetramethyl benzidine in 100 mM sodium acetate, pH 6.0) added prior to quenching with 2 N H 2 SO 4 . Absorption was read at 450 nm within 30 min of quenching. The intra-assay precision was 6.3% relative standard deviation, inter-assay precision was 8.6% relative standard deviation and the detection limit of the assay was 7.5 pg/ml.
Assay for IL-8
IL-8 was measured by ELISA, utilizing matched pairs of capture and biotinylated-labelled detection antibodies against IL-8 (R&D Systems, Oxford, UK) (Denison et al., 1997) . Briefly, plates were coated overnight at 4°C with capture antibody, washed once in water, and coating solution added for 30 min at 23°C. The coating solution was removed and the plates stored as for MCP-1. Prior to use, the plates were washed once in water. Samples and standards (recombinant standards; Toray Industries Inc.; diluted in ELISA buffer) were added, with the top standard being 500 pg/ml. Plates were incubated for 3 h at 23°C on an orbital shaker, washed as above, then detection antibody (30 ng/ml in ELISA buffer) was added and plates were incubated on a shaker for 45 min at 23°C. After a further wash, streptavidin peroxidase (Boehringer Mannheim) was added at 0.02 U/well and plates were incubated for 20 min at 23°C on an orbital shaker. They were then washed, substrate was added and were read as for MCP-1. The intra-and inter-assay precisions were 9.1% relative standard deviation and 22.1% relative standard deviation respectively, and the detection limit of the assay was 7.5 pg/ml.
Assay for RANTES
This assay has been performed previously in this laboratory and has been described in detail (Denison et al., 1997) . The capture antibody (coated at 2 µg/ml), standards (recombinant, top standard 500 pg/ml) and detection antibody (added at 50 µg/ml) were all obtained from R&D Systems. The intra-and inter-assay precisions for this assay were 10.4% relative standard deviation and 11.2% relative standard deviation respectively, and the detection limit of the assay was 7.5 pg/ml.
Assay for IL-10
All dilutions were in 10% fetal calf serum in PBS unless otherwise stated. Plates were coated with capture antibody (Pharmingen, San Diego, USA; 200 ng/ml in PBS) added at 100 µl/well for 60 min at 23°C, then blocked (10% fetal calf serum in PBS) at 300 µl/well for a further 60 min at 23°C. The plates were then washed and both samples and standards (recombinant; Pharmingen) added with the top standard being 500 pg/ml. Plates were then incubated on an orbital shaker for 60 min, washed, detection antibody (Pharmingen, San Diego, CA, USA, 100 µl; 125 ng/ml) was added and incubated for 60 Normally T-cells Expressed and presumably Secreted) and interleukin-10 (IL-10) from the amnion, chorion, placenta and decidua. Significantly higher concentrations of MCP-1 were released by the chorion (P Ͻ 0.001), placenta (P Ͻ 0.001) and decidua (P Ͻ 0.001) than from the amnion respectively. RANTES was secreted in significantly greater amounts from the decidua (P Ͻ 0.01) and placenta (P Ͻ 0.01) than from the chorion. The majority of IL-10 was released by the chorion and decidua with lower but non-significant concentrations from the placenta. Neither RANTES nor IL-10 were released by the amnion. Significance: a, P Ͻ 0.001; b, P Ͻ 0.01; n ϭ 7 different women. Values are expressed as pg/mg wet weight Ϯ SEM. min at 23°C. After a further wash, polyperoxidase (CLB laboratories, Amsterdam, The Netherlands; 100 µl; 1 ng/ml in ELISA buffer without Tween) was added for 30 min. Finally, plates were washed and read as for MCP-1. The intra-and inter-assay variations were 6.4% and 10.1% respectively, and the detection limit of the assay was 7.5 pg/ml.
Statistical analysis
Statistical analysis of the tissue explant data was performed using analysis of variance and a Student's paired t-test was used for the placental perfusion model (Statview 4.1, Abacus Inc., Berkeley, CA, USA). The data were normally distributed and are expressed as pg/mg wet weight (mean Ϯ SEM) with a statistically significant difference defined as P Ͻ 0.05.
Results
Tissue explants
Explants of amnion, chorion, decidua and placenta exhibit distinct profiles of cytokine release (see Figure 1) . Significantly higher concentrations of MCP-1 were released by the chorion (78.2 Ϯ pg/mg wet weight; P Ͻ 0.001), decidua (112.4 Ϯ 5.2 pg/mg; P Ͻ 0.001) and placenta (101.8 Ϯ 5.0 pg/mg; P Ͻ 0.001) than from the amnion (1.3 Ϯ 0.4 pg/mg). IL-8 was secreted in large amounts by all tissues studied with release from the chorion, decidua, placenta and amnion being 52.8 Ϯ 1.9 pg/mg, 42.2 Ϯ 1.5 pg/mg, 45 Ϯ 1.3 pg/mg and 39.9 Ϯ 5 respectively. The placenta (26.9 Ϯ 1.6 pg/mg) and decidua (15.2 Ϯ 1.4 pg/mg) were the principal sources of RANTES, 3562 with significantly more being released than by the chorion (6.0 Ϯ 1.2 pg/mg; P Ͻ 0.01). IL-10 was released mainly by the chorion (6.8 Ϯ 0.8 pg/mg) and decidua (9.0 Ϯ 0.9 pg/mg) with concentrations which were lower, but which failed to reach significance, from the placenta (3.3 Ϯ 0.3 pg/mg). Neither RANTES nor IL-10 were released in detectable concentrations by the amnion. The ratio of MCP-1:IL-8 release by the amnion was 1:31 and the ratios of MCP-1:IL-8: RANTES: IL-10 release by the chorion, placenta and decidua were 13:9:1:1, 31:14:8:1 and 12:5:2:1 respectively.
Placental perfusion
The basal cytokine output from the perfused placental cotyledon (maternal and fetal combined) prior to commencing the PGE 2 infusion was less than that by placental explants for MCP-1, IL-8 and IL-10 (relative ratios 1:4; 1:13; 1:2) but not for RANTES (relative ratio 1:1). The basal output of all cytokines measured was greater from the maternal than the fetal circulation in the perfusion system, with the ratios of basal output of MCP-1, IL-8, RANTES and IL-10 between maternal and fetal circuits being 145:1, 79:1, 7:1 and 2:1 respectively. The differential release of cytokines between the two circulations was maintained for the duration of the perfusion and study period.
Perfusion of placentae with PGE 2 significantly (P Ͻ 0.01) stimulated release of IL-8, MCP-1 and IL-10 from the maternal and IL-8 and MCP-1 from the fetal circulation. The stimulation became significant~20 min after commencing the PGE 2 infusion and was maintained for the duration of the perfusion and study period (Figures 2a, b and 3) .
RANTES was released into both the maternal and fetal circulation, but secretion was not affected by infusion of PGE 2 , unlike the other cytokines measured (Figures 2a, b) .
Discussion
The heterogeneous intrauterine structures present during the third trimester originate from both maternal and fetal tissue and have widely differing functions. In this study it has been demonstrated that third trimester amnion, chorion, decidua and placenta explants secrete quite distinct cytokine profiles. MCP-1 was released predominately by the chorion, decidua and placenta with low amounts from the amnion (relative ratios 62:94:85:1 respectively). High concentrations of IL-8 were released by the amnion, chorion, decidua and placenta (relative ratios 1:1:1:1 respectively). Release of RANTES was not detectable from the amnion but was detected in moderate amounts from the chorion, decidua and placenta (relative ratios 1:3:4). Low concentrations of IL-10 were secreted by the chorion, decidua and placenta with none detectable from the amnion (relative ratios 2:3:1).
The fetal membranes comprise the amnion and chorion. The amnion, which is composed of an epithelial and fibroblast layer, released both IL-8 and MCP-1. Local release of IL-8 from unstimulated (Laham et al., 1997) and cytokine-stimulated amnion explants (Trautman et al., 1992) has been demonstrated previously and has been postulated to have a role in parturition. The demonstration of MCP-1 release is, however, novel and Figure 2 . Effect of prostaglandin E 2 (PGE 2 ) infusion on the release of monocyte chemotactic peptide-1 (MCP-1), interleukin-8 (IL-8), RANTES (Regulated on Activation and Normally T-cells Expressed and presumably Secreted) into (a) the maternal and (b) the fetal circulation in a dynamic dually perfused placental cotyledon. The release of MCP-1 and IL-8 release was significantly (P Ͻ 0.01) stimulated into both maternal and fetal circulations~20 min after commencing the PGE 2 infusion and concentrations continued to be elevated until the end of the study period. The PGE 2 infusion had no effect on RANTES release. Significance: a, P Ͻ 0.01; n ϭ 8 different placentae. Values are expressed as pg/min/cotyledon Ϯ SEM.
could be from either epithelium or fibroblasts, both of which are capable of its synthesis in extra-uterine sites (Elner et al., 1997) .
The chorion, whose principal constituent is the trophoblast, released all cytokines measured. IL-8 release has been demon- Figure 3 . Effect of prostaglandin E 2 (PGE 2 ) infusion on the release of interleukin-10 (IL-10) into the maternal and fetal circulation in dually perfused placental cotyledon. The release of IL-10 was significantly (P Ͻ 0.01) stimulated into the maternal circulatioñ 20 min after commencing the PGE 2 infusion and concentrations continued to be elevated until the end of the study period. There was no rise in concentrations of IL-10 in the fetal circulation postinfusion. Significance: a, P Ͻ 0.01; n ϭ 8 different placentae. Values are expressed as pg/min/cotyledon Ϯ SEM. strated previously and has been immunolocalized in cytokinestimulated chorion to the trophoblast, stromal fibroblasts and macrophage-like cells (Ito et al., 1994) . The release of IL-10 by the chorion contrasts with the findings of others (Trautman et al., 1997) who were not able to demonstrate its release and only rarely its immunolocalization within the chorion. However, they readily detected IL-10 in the decidua, and it may be that the decidua adherent to the chorionic trophoblast is responsible for IL-10 release in these explant preparations.
The decidua released high concentrations of MCP-1 and IL-8 and moderate concentrations of RANTES and IL-10. The release and immunolocalization of IL-8 and IL-10 has been demonstrated previously within the decidua (Saito et al., 1994; Trautman et al., 1997) . Although the decidua comprises a wide range of different cell types, it is likely that decidual macrophages and T-cells would be the principal source of MCP-1 and RANTES respectively.
The placenta released high concentrations of MCP-1, IL-8 and RANTES and low concentrations of IL-10. Secretion of IL-8 and IL-10 by the placenta supports previous data demonstrating release and localization of IL-8 to the cytotrophoblast, the syncytiotrophoblast, perivascular cells and placental Hofbauer cells (Saito et al., 1994; Elliott et al., 1998) and of IL-10 to the cytotrophoblast (Roth et al., 1996) . Although release of MCP-1 and RANTES protein by the placenta has not been reported before, a novel chemokine receptor CCR10 has been detected recently, which binds MCP-1 with high affinity and RANTES with much lower affinity. This receptor is uniquely expressed within placenta and fetal liver (Bonini et al., 1997) . A variety of cells within the placenta would be capable of secreting MCP-1 and RANTES, including the trophoblast, placental macrophages and T-cells. However, some placental explants were contaminated with blood, and therefore peripheral leukocytes, in particular monocytes and T-cells, could be an additional source of MCP-1 and RANTES respectively.
Parturition has been likened to an inflammatory reaction, with cytokines such as IL-8 playing a key role in cellular recruitment and activation within the utero-placental unit at term (Sennstrom et al., 1997) . Prostaglandin E 2 is also thought to be an important mediator and possible initiator of parturition, with concentrations increasing peripartum within amniotic fluid, placenta and cervix. In extra-uterine inflammatory responses, synergy exists between PGE 2 and IL-8 to facilitate neutrophil recruitment (Colditz, 1990) . Furthermore, IL-8 release can be up-regulated by PGE 2 (Agro et al., 1996) and, although the mechanism is not well defined, it may be via PGE 2 stimulation of cAMP (Brar et al., 1997; Kaveleers et al., 1997) . Whether PGE 2 regulates release of other inflammatory mediators, such as MCP-1 and RANTES, which may also be involved in parturition is not known.
In this study it was investigated whether PGE 2 regulated release of MCP-1, IL-8, RANTES and IL-10 within the placenta and also its effect on cytokine release from a dually infused placental cotyledon. This demonstrated that PGE 2 stimulated release of MCP-1 and IL-8 into the maternal and fetal circuits of the perfusion system but had no effect on RANTES release. It can be postulated that a rise in PGE 2 at term would stimulate MCP-1 and IL-8 release, thus promoting a local inflammatory reaction and favouring parturition. The principal source of cytokines in such a system would be the trophoblast, although there may be a slight contribution from the decidua of the basal plate. The effect of PGE 2 stimulation of cytokine release into the fetal circulation was less than into the maternal circulation, and this could be due to inefficient transport of PGE 2 across the trophoblast, inability of cells adjacent to the fetal circulation, such as the Hofbauer cells, to respond by stimulation to PGE 2 , or metabolism of PGE 2 by the trophoblast (Cheung et al., 1990) . RANTES secretion was not stimulated by PGE 2 . This further supports the hypothesis that stimulation of IL-8 and MCP-1 was secondary to PGE 2 and not an artefact of perfusion.
In addition, PGE 2 stimulated release of IL-10 into the maternal but not the fetal circulation. The maternal immune system maintains tolerance to the fetus throughout pregnancy, although the mechanism is poorly understood. IL-10 is present in amniotic fluid in increasing quantities during pregnancy (Greig et al., 1995) and, because of its immunosuppressive properties (Mosmann and Moore, 1991) , has been proposed as a factor which may be involved in preventing fetal rejection (Rivera et al., 1998) . In other systems, PGE 2 is a potent stimulator of IL-10 and inhibitor of IL-12, a pro-inflammatory cytokine which favours a TH-1 or cell-3564 mediated immune response (Trinchieri, 1993) . A rise in IL-10 and fall in IL-12 concentrations favour immunosuppression and can induce anergy or non-recognition of antigen by Tcells (Groux et al., 1996) . We propose that, at term, stimulation of IL-10 release from the maternal side of the placenta by PGE 2 would enhance local immunosuppression and tolerance towards fetal antigen. The fetus would then be protected from maternal recognition and rejection during the 'high risk' inflammatory process of parturition.
In summary, it has been demonstrated that the amnion, chorion, placenta and decidua release distinct profiles of both pro-and anti-inflammatory cytokines. Furthermore, in-vitro perfusion of a placental cotyledon by PGE 2 stimulates release of IL-8, MCP-1 and IL-10, but not RANTES. We speculate that the pro-inflammatory cytokines MCP-1 and IL-8 may play a role in the inflammatory process of parturition and that the anti-inflammatory IL-10 may be involved in protecting the fetal allograft at parturition. Moreover, we suggest that PGE 2 may play an important immunomodulatory role within the placenta at term. Further studies are now underway to assess the effect of PGE 2 and other immunomodulators on cytokine release by the amnion, chorion, decidua and placenta.
